- Moleculin Biotech Inc (NASDAQ:MBRX) announced that its WP1096 molecule would be evaluated in animal studies by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
- Moleculin studies WP1096 as a novel potential therapy for a broad spectrum of viruses, including arenaviruses.
- WP1096 is a compound within the WP1122 portfolio.
- WP1122 molecule is a prodrug of 2-deoxy-D-glucose (2-DG), and 2-DG has been approved outside the U.S. for use as a treatment for COVID-19.
- Moleculin is currently conducting a Phase 1 trial of analog WP1122 (a prodrug of 2-DG) in healthy volunteers in preparation for a Phase 2 trial in COVID-19 patients.
- Between its antiviral effort with WP1122 and a range of oncology-focused initiatives, Moleculin cannot allocate significant resources to developing WP1096.
- However, considering the promising WP1096 in vitro activity in a range of potentially deadly viruses previously demonstrated, Moleculin believes that WP1096 would be a good candidate for animal testing in arenavirus models where there is a significant unmet need.
- If WP1096 demonstrates significant efficacy in the requested animal studies, Moleculin intends to revise its current development strategy to accelerate development work on WP1096.
- Price Action: MBRX shares are down 1.84% at $1.13 on the last check Tuesday.
Citigroup Maintains Buy on DocuSign, Lowers Price Target to $68
Citigroup analyst Tyler Radke maintains DocuSign (NASDAQ:DOCU) with a Buy and lowers the price target from $90 to $68.
